Metformin in Alzheimer's Dementia Prevention (MAP)

Brief description of study

The purpose of this study is to test whether the drug Glucophage® XR (generic name metformin extended-release tablets) can prevent cognitive decline among persons with mild cognitive impairment. Mild cognitive impairment is defined as the presence of cognitive complaints, such as forgetfulness, accompanied by mild deficits in tests of memory, and without affecting the ability to live independently. Metformin is approved by the Food and Drug Administration (FDA) for the treatment of type 2 diabetes, but is also used "off-label" for the prevention of diabetes among persons at risk, for the treatment of fatty liver, and for the treatment of polycystic ovarian syndrome. Metformin is not approved for prevention of cognitive decline.


Clinical Study Identifier: s19-02013
ClinicalTrials.gov Identifier: NCT04098666
Principal Investigator: Arjun V. Masurkar.


If you are registered as a volunteer, please log in to contact the study team/express interest in this study.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.